Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michigan Bone
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates
Authors Authors and affiliations P.D. Miller N. Pannacciulli J. Malouf-Sierra A. Singer E. Czerwiński H.G. Bone C. Wang S. Huang A. Chines W. Lems J.P. Brown Original Article First Online: 28 November 2019 Shares 226 Downloads Abstract Summary Transitioning postmenopausal women with osteoporosis from a bisphosphonate to denosumab appears to be safe and more effective at improving BMD than continuing treatment with a bisphosphonate.
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
Authors Authors and affiliations D.L. Kendler H.G. Bone F. Massari E. Gielen S. Palacios J. Maddox C. Yan S. Yue R.V. Dinavahi C. Libanati A. Grauer Open Access Original Article First Online: 18 October 2019 Abstract Summary Romosozumab is a therapy that stimulates bone formation and reduces bone resorption.
Denosumab treatment in postmenopausal women with osteoporosis - Authors' reply
We note Yu Zhang and Rongrui Tang's criticism of the use of a placebo control group in the original FREEDOM trial,1 which was followed by a 7-year open-label extension, the subject of our Article. FREEDOM was initiated in 2004, was conducted in compliance with Food and Drug Administration and European Medicines Agency regulatory guidance,2, 3 and was reviewed and approved by the Ethics Committee or equivalent for every participating site.
Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension - Watts - 2017 - Journal of Bone and
Denosumab is a fully human monoclonal antibody against RANKL that decreases osteoclast formation, function and survival, and is approved for the treatment of postmenopausal women with osteoporosis at increased or high risk for fracture, among other indications.
Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation
Healthy male and female subjects were chosen as participants for this study in compliance with FDA guidance for in vivo pharmacokinetic and bioavailability studies using LT4 tablets. Most patients administered alendronate are postmenopausal women who are older than the subjects in this study. Alendronate is also approved in the USA for treatment to increase bone mass in men, so it was appropriate to include men in this study.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michigan
Contact Michigan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack